Trials / Active Not Recruiting
Active Not RecruitingNCT03355560
Adjuvant Nivolumab After Salvage Resection in Head and Neck Cancer Patients Previously Treated With Definitive Therapy
A Single Arm Phase 2 Study of Adjuvant Nivolumab After Salvage Resection in Head and Neck Squamous Cell Carcinoma Patients Previously Treated With Definitive Therapy
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 39 (estimated)
- Sponsor
- Trisha Wise-Draper · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to test the safety and efficacy of nivolumab after salvage resection in head and neck cancer in patients that have previously received definitive radiation with or without chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nivolumab | Nivolumab 480 mg IV infusion |
Timeline
- Start date
- 2017-12-06
- Primary completion
- 2024-01-01
- Completion
- 2024-07-01
- First posted
- 2017-11-28
- Last updated
- 2024-02-28
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03355560. Inclusion in this directory is not an endorsement.